Published in Vaccine Weekly, November 1st, 2006
"In contrast, loss of immunogenic epitopes of tumor cells has urged the development of vaccines against multiple epitopes. In this study, we developed a novel strategy for the APC to efficiently cross-present a fusion tumor antigen, which contains both MHC class...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly